Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

Rhea-AI Summary

Hikma Pharmaceuticals (OTC:HKMPY) has announced a significant $1 billion investment to expand its US manufacturing and R&D capabilities by 2030. The initiative, dubbed "America Leans on Hikma," builds upon the company's 34-year presence in the US market and aims to enhance domestic production of essential generic medicines.

The company currently operates facilities in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey. Hikma has invested over $4 billion in the past 15 years and has the capacity to produce more than 12 billion finished doses annually. As a top three US supplier of sterile injectable medicines, Hikma maintains a portfolio of over 800 medicines, including more than 180 injectable products.

Positive

• Substantial $1 billion investment commitment through 2030 for US manufacturing expansion
• Current capacity to produce over 12 billion finished doses annually
• Strong market position as top 3 US supplier of sterile injectable medicines
• Extensive portfolio of 800+ medicines including 180+ injectable products
• Proven track record of FDA quality inspections and addressing drug shortages

Negative

• None.

Insights

Pharmaceutical Industry Analyst

Hikma's $1B US expansion strengthens domestic supply chain position, boosting production capacity and competitiveness in generic medicines market.

Hikma's $1 billion investment plan through 2030 represents a significant strategic expansion of its US footprint, building on its already substantial domestic operations. The company currently produces over 12 billion finished doses annually and offers more than 800 medicines in its portfolio. This investment follows $4 billion already spent over the past 15 years on US capabilities.

The expansion targets both R&D and manufacturing across facilities in Ohio and New Jersey, which should strengthen Hikma's competitive position in two key segments: generic pharmaceuticals and sterile injectables. Notably, the company has already achieved a top three position in US sterile injectables by volume, with 180 injectable products currently in its portfolio.

This investment is particularly strategic given the ongoing national focus on pharmaceutical supply chain security and domestic manufacturing capabilities. Hikma's emphasis on its role in addressing drug shortages and its track record with FDA inspections positions it favorably amid policy discussions about reducing dependency on foreign pharmaceutical manufacturing.

The company's bipartisan political support, evidenced by the presence of Representatives from both parties at the announcement, also suggests potential regulatory tailwinds. The backing from Rep. Carter, who chairs the American-Made Medicines Caucus, indicates alignment with current political priorities around domestic pharmaceutical production.

This expansion should enhance Hikma's economies of scale, potentially improving margins while simultaneously increasing its capacity to capture greater market share in the competitive US generics space.

Next phase builds on 34+ years of serving the needs of US patients and healthcare providers

COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.

Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages. 

Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio.

America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. 

"We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines." 

Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients."

"As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter. 

"Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said.

Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans.

Contacts :        

Hikma Pharmaceuticals PLC   

Investors Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 7776 477050
Media Steven Weiss US Communications	+1 732 788 8279

About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/hikma-pharmaceuticals-usa-announces-1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines-302493824.html

SOURCE Hikma Pharmaceuticals USA Inc.

FAQ

What is the size of Hikma Pharmaceuticals' (HKMPY) new US investment and when will it be completed?

Hikma announced a $1 billion investment to expand its US manufacturing and R&D capabilities, to be completed by 2030.

How many medicines does Hikma currently produce in the US?

Hikma maintains a portfolio of over 800 medicines, including more than 180 injectable products, with capacity to produce over 12 billion finished doses annually.

Where are Hikma's US manufacturing facilities located?

Hikma operates manufacturing and R&D facilities in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey.

How much has Hikma invested in US operations over the past 15 years?

Hikma has invested more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities.

How many employees does Hikma have in the US?

Hikma employs 2,300 people across its US operations.